The customer is a global company developing innovative medicines and vaccines using advanced mRNA technology. The collaboration is currently in the development phase and includes the use of Bio-Works’ products and expertise in the purification of biological medicines.

The customer’s decision to proceed with Bio-Works means that the company’s solutions will be used in the continued development of the drug candidate. The project has the potential to grow if drug development progresses according to plan.

"We are very pleased to have earned the trust of another leading US biotechnology company. The order, valued at SEK 2.8 million, is an important validation of Bio-Works’ technical expertise and our ability to meet the stringent requirements associated with the development and manufacturing of advanced biological medicines," says Lone Carlbom, CEO of Bio-Works.

The collaboration strengthens Bio-Works’ position in the US market and within the rapidly growing field of next-generation medicines. The customer’s identity and further details of the project cannot be disclosed due to commercial confidentiality.

For further information

Lone Carlbom, CEO, Bio-Works Technologies AB
Telephone: +46 (0)8-502 705 84
Email: lone.carlbom@bio-works.com

About Bio-Works

Bio-Works helps the biotechnology industry achieve its biomolecule purification objectives. We support our customers from laboratory research through to commercial production, working together to implement efficient and robust bioprocessing solutions. Our vision is to be a trusted and dynamic partner to an industry undergoing growth and development.

Bio-Works’ headquarters, including R&D and manufacturing, are located in Uppsala Business Park in Uppsala, Sweden. We supply our products to a global market through a combination of direct sales and distributors in Europe, North America and Asia. The company is certified in accordance with the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market under the ticker "BIOWKS".

For further information, please visit www.bio-works.com.

This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-08-2026 08:57 CET.